Cargando…

Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress

Immune checkpoint inhibitor-associated adverse reactions (irAEs) are a clinical treatment issue that requires additional attention when ICIs have significant survival benefits in patients with advanced hepatocellular carcinoma (HCC). Among them, ICIs-associated myocarditis (ICIAM) is a kind of sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Hongxiang, Wen, Zhijian, Liu, Bin, Chen, Hongbiao, Lin, Qian, Chen, Zhan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458972/ https://www.ncbi.nlm.nih.gov/pubmed/36091070 http://dx.doi.org/10.3389/fimmu.2022.995121

Ejemplares similares

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
por: Wan, Yanzhi, et al.
Publicado: (2023)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
por: Ai, Qi, et al.
Publicado: (2022)

Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
por: Wen, Liang, et al.
Publicado: (2020)

Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review
por: Wang, Min, et al.
Publicado: (2022)

Case report: Advanced primary squamous cell carcinoma in the periampullary area with upregulation of programmed cell death-ligand 1 expression and response to sintilimab immunotherapy
por: Wang, Baoshan, et al.
Publicado: (2023)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
por: Hong, Guo, et al.
Publicado: (2023)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
por: Liu, Lulu, et al.
Publicado: (2023)

Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report
por: Li, Gang, et al.
Publicado: (2022)

Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report
por: Liu, Chenxi, et al.
Publicado: (2021)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
por: Lye, Ya-lei, et al.
Publicado: (2023)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report
por: Lin, Yunling, et al.
Publicado: (2022)

Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022)

HBV-Induced Immune Imbalance in the Development of HCC
por: Chen, Yongyan, et al.
Publicado: (2019)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
por: Liu, Chengxin, et al.
Publicado: (2023)

Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma
por: Li, Xueqin, et al.
Publicado: (2023)

Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy
por: Chouik, Yasmina, et al.
Publicado: (2023)

The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications
por: Sajid, Muhammad, et al.
Publicado: (2022)

Efficacy and Biomarker Exploration of Sintilimab Combined With Chemotherapy in the Treatment of Advanced Penile Squamous Cell Carcinoma—A Report of Two Cases
por: Mei, Xinkuan, et al.
Publicado: (2022)

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

Sintilimab: Aggravation of Coronavirus disease 2019: case report
Publicado: (2021)

Case report: A rare case of sintilimab-induced gastric stenosis and literature review
por: Song, Kunkun, et al.
Publicado: (2023)

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients
por: Yuan, Guosheng, et al.
Publicado: (2021)

New techniques: a roadmap for the development of HCC immunotherapy
por: Jiang, Dizhi, et al.
Publicado: (2023)

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC
por: Dong, Jianming, et al.
Publicado: (2023)

Research advance of natural products in tumor immunotherapy
por: Huo, Jin-Ling, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients
por: Feng, Yu-Min, et al.
Publicado: (2015)

Comprehensive analysis of the clinical significance, immune infiltration, and biological role of MARCH ligases in HCC
por: Cao, Jun, et al.
Publicado: (2022)

Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review
por: Lin, Si-Hong, et al.
Publicado: (2022)

Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7er22k5v6orbpqjqohtfauitoa